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Role of 1,25-dihydroxyvitamin D on the skeletal resistance to parathy-
roid hormone. Hypocalcemia in chronic renal failure (CRF) has been
attributed in part to a skeletal resistance (S.R.) to the calceniic action of
parathyroid hormone (PTH) as a consequence of low levels of 1,25
(OH)2D3. To further elucidate the role of 1 ,25(OH)2D3 in the genesis of
S.R., the calcemic effect of infusion of synthetic b-PTH 1- 34 was
examined in dogs before and after 7, 90 and 180 days of CRF. The
maximum increment in ionized calcium after the infusion of PTH in the
normal dogs was 1.15 0.13 mg/dl, decreased to 0.84 0.09 after 7
days, 0.68 0.1 after 90 days and to 0.66 0.11 mg/dI after 180 days
of CRF. Thereafter, the dogs received 1 ,25(OH)2D3, 0.5 sg daily for
seven days and the studies were repeated. No improvement in the
calcemic response to PTH was observed (0.57 0.26 mg/lOO ml).
Subsequently, a parathyroidectomy (PTX) was performed and 24 hours
later the studies were repeated. After the infusion of PTH the calcemic
response returned to normal (0.93 0.14 mgldl). Further studies were
performed in a group of four uremic dogs receiving no 1 ,25(OH)2D3, in
which a PTX was performed 24 hours prior to the infusion of PTH. For
this group, the increase in serum ionized calcium was 0.99 0.11 mg/dl.
These values were not statistically different from normal dogs. In
summary: (1) renal insufficiency was characterized by an abnormal
calcemic response to PTH; (2) the administration of I ,25(OH)2D3 did
not correct the S.R. to PTH; and (3) PTX performed 24 hours before the
infusion of PTH restored the calcemic response to normal. These data
suggest that high levels of endogenous parathyroid hormone desensi-
tized the skeleton to the administration of exogenous PTH. These
studies indicate that low values of I ,25(OH)2D3 are not directly respon-
sible for the skeletal resistance to PTH in chronic renal failure.
Chronic renal failure is characterized by secondary hyper-
parathyroidism, a finding which has been attributed to: 1)
phosphate retention [1—7]; 2) abnormal intestinal calcium ab-
sorption, secondary to reduced 1 ,25(OH)2D production [8]; 3)
skeletal resistance to the calcemic effects of PTH, due to either
decreased l,25(OH)2D levels or hyperphosphatemia [9—16]; 4)
altered set point for calcium-regulated PTH release [17—19]; 5)
impaired degradation of PTH [20, 211; and 6) impaired metab-
olism of PTH 1-84 to PTH 1-34 [22].
Skeletal resistance to PTH occurs in both acute and chronic
renal failure in patients and in experimental animals [10—12]. In
thyroparathyroidectomized dogs, the blunted calcemic response
was observed at on to three days after bilateral nephrectomy
and was reversed partially by administration of 1 ,25(OH)2D [12]
Received for publication April 13, 1987
and in revised form July 16, 1987
© 1987 by the International Society of Nephrology
and not affected by 24-25(OH)2D, but the combination of
I ,25(OH)2D and 24-25(OH)2D fully reversed the abnormality
[13]. Moreover, when acute uremia was produced by bilateral
ureteral ligation rather than bilateral nephrectomy, the defect
was fully corrected by 1 ,25(OH)2D alone [14].
Somerville and Kaye [15] have obtained different results in
rats; resistance to the calcemic action of PTH was demon-
strated as early as five hours after bilateral nephrectomy or
ureteral ligation, when circulating 1 ,25(OH)2D and 24-25(OH)2D
levels were normal. Administration of I ,25(OH)2D in combina-
tion with 24-25(OH)2D did not alleviate the defect, although
l,25(OH)2D did cause some improvement in a chronic renal-
failure model (28 days). The same authors [16] have reinfused
urine to produce acute uremia and have reproduced PTH
resistance at five hours. Treatment of the urine with zirconium
oxide, which is presumed to remove phosphate, completely
reversed the abnormality. These results suggest a direct role of
phosphate in skeletal resistance to PTH.
Proportional reduction of dietary phosphate in chronic ure-
mic dogs have shown to prevent or improve the development of
secondary hyperparathyroidism [231. Established secondary
hyperparathyroidism in the dog may also be reversed by dietary
phosphate restriction [24]. Kaplan and collaborators [25] sug-
gested that skeletal resistance to the calcemic effect to PTH
persists in proportional phosphate restriction even though hy-
perparathyroidism is prevented [25]. In contrast, Liach and
Massry [5] found that prolonged (60 days) dietary phosphate
restriction in four patients with moderate renal insufficiency
improved hyperparathyroidism, intestinal calcium absorption,
calcemic response to parathyroid extract infusion, and in-
creased serum 1 ,25(OH)2D3 levels. These authors concluded
that an increase in the levels of 1 ,25(OH)2D3, induced by the
low phosphate diet, reverse the skeletal resistance to PTH.
The present studies were designed to further clarify the role
of l,25(OH)2D in the genesis of skeletal resistance to PTH in
dogs with chronic renal failure.
Methods
Study protocol
Experiments were performed in 17 female mongrel dogs
weighing 14 to 27 kg. All animals were maintained on Purina
high-protein diet containing 1.6% calcium, 0.95% phosphorus,
0.15% magnesium and 176 units of vitamin D per 100 g and they
ingested 400 g/day. The dogs were fasted overnight and cathe-
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N=9
Uremic
7 daysN=9 90 daysN=7 180 daysN=7
GFR mI/mm
Icamg/dl
SPO4 mg/dl
FEPO4 %
I-PTH piEqImi
59.7 1.84
4.91 0.07
3.45 0.32
3.92 1.17
42 4.15
8.65 1.9
5.05 0.09
5.1 0.21
67.4 4.7
106 8.77
15.0 3.37
5.3 0.12
5.8 0.68
43.8 7.24
187 21.4
15.0 4.2
4.8 0.1
6.04 0.71
54.0 4.01
307 22.6
ters were placed in the jugular and hind leg veins for blood
samples and a Foley catheter was inserted for urine collections.
After 20 minutes of equilibration, two control urine collections
for creatinine and phosphorus clearances were made. Following
the control period, syn-b-PTH 1-34 or vehicle was administered
as a priming dose of five units per kilogram intravenously,
followed by a sustaining infusion of four units per kilogram per
hour, for a period of six hours. Thereafter, six hourly urine-
collections were obtained for creatinine and phosphorus clear-
ances, and at the midpoint of each period, plasma samples for
the measurements of total and ionized calcium, phosphorus and
creatinine was collected anaerobically. After control studies
were performed in these dogs with normal renal function, renal
mass was reduced by ligating most of the terminal branches of
the left renal artery, and right contralateral nephrectomy, as
previously described [26—27]. Then, studies were repeated as
described above, at 7, 90, and 180 days of uremia. A group of
six dogs with intact parathyroid glands, with 180 days of uremia
and severe secondary hyperparathyroidism was treated with
1,25(OH)2D, 0.5 jsg/day for seven days and then infused with
syn-b-PTH 1-34 as previously described. Thereafter, a thy-
roparathyroidectomy (T-PTX) was performed, and 24 hours
later similar studies were performed. The effectiveness of the
surgical procedure was supported by the fall in plasma ionized
calcium in all the animals. A second group of four dogs with 180
days of chronic renal failure underwent T-PTX and 24 hours
later were infused with syn-b PTH 1-34 as previously described.
These animals did not receive 1 ,25(OH)2D3.
Chemical determinations
Ionized calcium was measured using an Orion electrode
(Orion Biomedical, Cambridge, Massachusetts, USA). Total
calcium was measured by atomic absorption spectrophotometry
(Model 503, Perkin Elmer, South Pasadena, California, USA).
Phosphorus was determined by a method [28—29] adapted for
the Technicon autoanalyzer (Model II, Technicon Instruments,
Tarrytown, New York, USA). Exogenous creatinine infusions
were used to determine glomerular filtration rate. Creatinine
was measured by the Jaffe reaction as described by Hawk et al
[30] and adapted for the Technicon autoanalyzer.
Sources and biological activity of PTH
Synthetic bovine PTH 1-34 (syn-b-PTH 1-34) was obtained
from (Beckman Instruments, Inc., Spinco Div., Palo Alto,
California, USA). The biological activity of syn-b-PTH 1-34
was assessed in the dog, renal-cortical cyclase assay [31].
Determination of i-PTH
Immunoreactive PTH was measured in serum by radioimmu-
noassay using the antibody CH9, which recognizes intact PTH
and PTH fragments from the middle, and carboxy-terminal
regions of the molecule as previously described [26, 27, 31].
Hyperparathyroid dog serum was used as assay standard.
Calculations
Results are expressed as mean SEM. Statistical analysis
was performed using Student's t-test for paired and unpaired
data as appropriate.
Results
Table 1 shows the baseline values in normal and uremic dogs
for glomerular filtration rate, ionized calcium, phosphorus,
fractional excretion of phosphate, and iPTH levels.
The mean GFR in the normal dogs was 59.7 1.84 ml/min.
The animals with remnant kidneys had a mean GFR of 8.7 1.9
mi/mm after seven days of uremia, and it increased to a mean of
15.0 3.37 mllmin after 90 and 15.0 4.2 after 180 days of
renal failure. Plasma ionized calcium was 4.91 0.07 mg/dl in
normal animals, and increased to 5.05 0.09 mg/dl after seven
days of uremia, and to 5.25 0.12 mg/dl after 90 days. Dogs
with 180 days of uremia showed a decrease in ionized calcium
to a value of 4.8 0.1 mg/dl. Plasma phosphorus was 3.45
0.32 mg/dl and rose to 5.1 0.21, 5.8 0.68 and 6.04 0.71
after 7, 90 and 180 days of uremia, respectively. Fractional
excretion of phosphate rose from 3.9 1.17% in normal dogs to
67.4 4.7%, 43.84 7.24%, and 53.99 4.01%, respectively,
in uremic animals.
Table 1. Baseline values in normal and uremic dogs
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Fig. 1. Calcemic response (Ca) to syn-b-PTH 1-34 in a group of 9
normal dogs (0, N = 9) and 7 uremic dogs (•, N = 7). The uremic
dogs have renal insufficiency for only 7 days.
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Immunoreactive PTH was 42 4.15 piEq/ml and gradually
increased to 106 8.77 jdEq/ml, 187 21.5 piEq/ml and 307
22.6 piEq/ml after 7, 90, 180 days of uremia, respectively.
Effect of infusion of syn-b-PTH 1-34 on plasma ionized
calcium in normal and chronic renal failure dogs
In order to document the time course of the development of
the impaired calcemic response to PTH in CRF, studies of the
calcemic response to PTH were performed prior to (N = 9) and
after 7, 90 and 180 days of CRF (N = 7).
Infusion of syn-b-PTH 1-34 to normal dogs produced a mean
rise in serum ionized calcium of 1.15 0.13 mgldl (range 0.69 to
1.77 mg/dl). Serum ionized calcium rose less after seven days of
renal failure; syn-b-PTH 1-34 caused a mean increase of 0.88
0.08 mgldl (range 0.26 to 1.29 mgldl). The values, however,
were not statistically different (Fig. 1).
After 90 and 180 days of uremia the infusion of syn-b-PTH
1-34 caused a mean increase in ionized calcium of 0.68 0.11
mgldl, (range 0.18 to 1.12 mgldl) and 0.65 0.11 mgldl (range
0.29 to 1.17 mgldl), respectively. These values were statistically
significant from normal (P < 0.001 to 0.01) (Figs. 2, 3).
Thus, an impaired calcemic response to PTH was clearly
demonstrable at 90 days of CRF and remained evident at 180
days of CRF.
Effect of infusion of syn-b-PTH 1-34 on plasma ionized
calcium in chronic renal failure dogs receiving 1 ,25(OH)2D3
In order to evaluate the effect of 1 ,25(OH)2D3 therapy on the
impaired calcemic response to PTH, additional studies were
performed. Six dogs with CRF for 180 days were treated with
1,25(OH)2D3 for seven days.
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Fig. 3. Calcemic response (Ca) to syn-b-PTH 1-34 in a group of
normal dogs (0, N = 9) and 7 uremic dogs (•, N = 7) after 180 days
of renal failure. Symbols are: (*) P < 0.05; (**) P < 0.02.
In these animals, PTH infusion caused a mean increase in
serum ionized calcium of 0.57 0.11 (range 0.18 to 0.81 mg/dl).
These values were statistically significant versus normal (P <
0.001 to 0.01, Fig. 4) but not significantly different from the
values obtained in dogs which did not receive therapy with 1,25
(OH)2D3.
These studies show, therefore, that supplementation with
pharmacological dose of 1 ,25(OH)2D did not improve the cal-
cemic response to PTH in animals with CRF.
Effect of parathyroidectomy on the calcemic response to
syn-b-PTH 1-34 in CRF
To further investigate the factors involved in the impaired
calcemic response to PTH, studies were performed to evaluate
the role of hyperparathyroidism. Studies were performed in two
groups of animals. The first group were the animals injected
with l,25(OH)2D1 (above). In these animals, the calcemic
response to PTH was assessed 26 hours after thyroparathyroid-
ectomy.
The increase in serum ionized calcium in response to syn-b-
PTH 1-34 was 0.94 0.14 mgldl (range 0.6 to 1.52 mgldl),
values not statistically different from normal animals (Fig. 5),
but significantly different from that of CRF animals with intact
parathyroid glands (P < 0.01). Thus, acute TPTX restored the
calcemic response to PTH to normal.
In order to exclude an effect of the prior treatment with
1 ,25(OH)2D3 on the improvement in the calcemic response to
PTH, additional studies were performed in four dogs with 180
days of CRF receiving no l,25(OH)2D3.
In this group, the increase in serum ionized calcium was 0.99
0.11 mg/dl (range 0.91 to 1.06 mgldl). These values were not
statistically different from normal (Fig. 6), but again were
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Fig. 2. Calcemic response (Cat ) to syn-b-PTH 1-34 in a group of
normal dogs (0, N = 9) and 7 uremic dogs (•, N = 7) after 90 days of
rena/failure. Symbols are: (*) P < 0.02; (**) P < 0.01; (***) P < 0.001.
—0.1
1 2 3 4 5 6
Time, hours
804 Galceran et al
0.7
E
+
+
o 0.5
U)
E
+
0
(I)
1.3
1.1
0.9
**
*
b-PTH 1-34
0.3
0,1
—0.1 2 3 4 5 6
Time, hours
Fig. 4. Calcemic response (Ca) to syn-b-PTH 1-34 in 9 normal dogs
(0) and 6 uremic dogs (I) (180 days of renal failure) receiving
1,25(OH)2D3 0.5 j.rg i.v. for 7 days before PTH administration. The
administration of pharmacologic doses of 1 .25(OH)2D3 did not correct
the abnormal calcemic response in the uremic dogs. Symbols are: (*)
P < 0.02; (**) P < 0.001; (***) P < 0.001.
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Fig. 6. Calcemic response (Ca4) to syn-b-PTH 1-34 in 9 normal dogs
(0) and 4 uremic dogs (•) (180 days of renal failure). The uremic dogs
did not receive 1 ,25(OH)2D3. A T-PTX was performed 24 hrs before
PTH administration.
to PTH infusion to levels similar to those seen in normal
animals, independent of therapy with 1 ,25(OH)2D3.
Discussion
Hypocalcemia, due to retention of phosphate and/or to de-
creased synthesis of 1 ,25(OH)2D3 by the diseased kidney, plays
an important role in the increased secretion of parathyroid
hormone in uremia.
Skeletal resistance to the calcemic effect of PTH, due o
either decreased 1 ,25(OH)2D3 levels or hyperphosphatemia,
appears in both acute and chronic renal failure in patients as
well as in experimental animals. This has been proposed as a
major pathogenetic factor in the development of secondary
hyperparathyroidism [10-12]. Previous studies have shown that
resistance to parathyroid hormone develops as early as 24 hours
in thyroparathyroidectomized dogs after bilateral nephrectomy
and is reversed partially by the administration of 1 ,25(OH)2D3
[12]. In rats [15], however, resistance to the calcemic action of
PTH has been observed as early as five hours after bilateral
nephrectomy, and the administration of 1 ,25(OH)2D3 in combi-
nation with 24,25(OH)2D3 did not ameliorate the defect, al-
2 3 4 5 6 though 1,25(OH),D3 did cause some improvement in a chronic
Time, hours renal-failure model.
In the studies described here, we examined parathyroid
Fig. 5. Calcemic response (Cat ) to syn-b-PTH 1-34 in 9 normal dogs . .
(0) and a group of 6 uremic dogs (•) (180 days of renal failure). After hormone resistance in dogs with chronic renal failure. Our
7 days of treatment with 1 ,25(OH)2D3 the dogs were T-PTX and PTH results show that the blunted calcemic response to syn-b-PTH
was administered as previously described. 1-34 infusion was observed at 90 and 180 days after the
induction of renal insufficiency; and the supplementation of
1 ,25(OH)2D3 failed to improve the calcemic response. If abnor-
significantly different from those uremic animals with intact mal vitamin D metabolism was the major factor in parathyroid
parathyroid glands. hormone resistance, the administration of 1 ,25(OH)2D3 would
These experiments clearly show that the thyroparathyroid- be expected to improve the calcemic response. This was not the
ectomy in chronic uremic dogs restored the calcemic response case (Fig. 4). We must indicate however, that the dogs de-
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Fig. 7. Summary of the calcemic response in normal dogs (D) and
uremic animals (•) under different experimental protocols.
scribed in reference 12 had bilateral nephrectomy or ureteral
ligation thus, the degree of uremia was more severe than the
one observed in our dogs. Stern et al [32] show that limb bones
from vitamin D-deficient rat fetuses resorb in response to
parathyroid hormone in vitro; and they suggested that the
impaired calemic response to parathyroid hormone seen in
vitamin D-deficient animals in vivo is not the result of a specific
unresponsiveness of vitamin D-deficient bone to parathyroid
hormone. Holtrop et al [33], demonstrated in vitamin D-def-
icient, thyroparathyroidectomized (TPTX) rats, that a physio-
logical dose of 1 ,25(OH)2D3 stimulates the activity of osteo-
clasts in the absence of parathyroid hormone. Thus, it would
seem that both PTH and 1 ,25(OH)2D3 can induce bone resorp-
tion independently.
Of interest, are the results obtained in the dogs after seven
days of renal insufficiency. Although there was a remarkable
decrease in the calcemic response to PTH, the values were not
significantly different from those obtained in the normal ani-
mals. Since, after one week of renal insufficiency the dogs have
mild secondary hyperparathyroidism (PTH 106 8.8 1slEq/nl),
it is possible that the skeleton still has a partial response to
exogenous PTH.
It is important to note, however, that the calcemic response
was restored when the chronic uremic dogs were subjected to
total parathyroidectomy 24 hours before the infusion of syn-b-
PTH 1-34. Therefore, the removal of the parathyroid glands, in
spite of the same uremic environment, restored the calcemic
response to syn-b-PTH 1-34 to levels similar to those seen in
normal animals (Fig. 7). These results suggest that high levels of
parathyroid hormone present in uremia desensitized the skele-
ton to the administration of exogenous PTH. Olgaard et al [34,
35] found that the isolated perfused tibia of acutely and chronic
uremic dogs responded with less release of cyclic AMP in
response to syn-b-PTH 1-34 than the tibia of normal animals.
When animals were subjected to acute thyroparathyroidec-
tomy, the release of cyclic AMP by bone in response to
syn-b-PTH 1-34 returned to normal levels, suggesting that
desensitization of the bone adenylate cyclase system to PTH
stimulation occurs in acute and chronic uremia. Previous stud-
ies have examined the mechanisms of PTH-induced desensiti-
zation in vitro and in vivo. Tamayo et al [36] demonstrated in
the isolated perfused dog kidney exposed to PTH for 16 to 20
hours that PTH receptor binding and PTH responsive adenylate
cyclase system of basolateral renal cortical membranes were
reduced compared to the control kidney. The refractory state to
PTH stimulation could be completely reversed by dissociation
of receptor-bound PTH by guanine nucleotides. These studies
demonstrated that persistent receptor occupancy could account
for the resistance to PTH in this experimental model. In other
experimental circumstances, different mechanisms for desensi-
tization may operate. Mahoney and Nissenson [37] have shown
that infusions of PTH to acutely uninephrectomized dogs re-
sulted in decreased PTH binding and PTH responsive adenylate
cyclase in renal cortical membranes of the remaining kidney
compared to that of the control kidney. These investigators did
not find evidence for receptor occupancy and concluded that
PTH receptor loss may account, at least in part, for the target
cell resistance to PTH. It should be noted, however, that the
decrease in PTH stimulated adenylate cyclase, exceeded the
decrease in receptor number suggesting that additional mecha-
nisms may also play a role. In a different experimental model of
chronic hyperparathyroidism, induced by feeding with low
calcium high phosphorus diet, Tamayo, Bellorin-Font and
Martin [38] have shown desensitization of renal cortical adenyl-
ate-cyclase to PTH also occurred. However, PTH receptor
binding was normal. Therefore, it appeared that dietary hyper-
parathyroidism resulted in renal resistance to PTH as a result of
'uncoupling' of the PTH receptor-adenylate cyclase system.
Recent studies in cultured chicken bone cells have shown that
the decrease in PTH binding and cAMP response to PTH as a
result of prior exposure to PTH in vitro may be due, at least in
part, to receptor mediated endocytosis of the hormone receptor
complex [39]. Thus, there appears to be substantial evidence
that exposure to high levels of PTH may result in target organ
resistance to the hormone. Regardless of the precise mecha-
nism (receptor occupancy, receptor loss, receptor mediated
endocytosis or uncoupling of the PTH receptor-adenylate cy-
clase system) the results obtained in our dogs indicates that
desensitization of bone cell receptors to high levels of circulat-
ing parathyroid hormone plays a key role in the skeletal
resistance to the administration of PTH in chronic renal failure.
Slatopolsky et al [2] were able to prevent the development of
hyperparathyroidism in the dogs with chronic renal failure by
decreasing the dietary phosphorus intake in proportion to the
fall in glomerular filtration rate. These studies have emphasized
the role of phosphorus homeostasis as the mediator of second-
ary hyperparathyroidism, but they did not evaluate the poten-
tial role of skeletal resistance to PTH. Recently, Lopez-Hilker
et al [40] have demonstrated that a low phosphate diet pre-
vented the increase in PTH release in dogs with chronic renal
failure, in spite of low levels of 1 ,25(OH)2D3 suggesting that
dietary phosphate restriction, in addition to changes in 1,
25(OH)2D3, may prevent the development of secondary hyper-
parathyroidism by an independent mechanism. Despite the role
that phosphate may play in the pathogenesis of skeletal resis-
tance to PTH, in our dogs with chronic renal failure, the
removal of the parathyroid gland restored to normal the calce-
mic response to PTH.
In conclusion: (1) dogs with chronic renal failure were found
7 days 180 days 1,25(OH)2D3
90 days 1,25(OH}2D3 +TPTX T-PTX
NS P<0.05 P<0.05 P<0.02 NS NS
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to have an abnormal calcemic response to biological active
syn-b-PTH 1-34; (2) the administration of pharmacological
doses of I ,25(OH)2D3 for one week does not correct the skeletal
resistance to PTH; and (3) parathyroidectomy returned the
calcemic response to normal suggesting that high levels of
endogenous parathyroid hormone desensitized the skeleton to
the administration of exogenous PTH. Thus, low levels of
circulating 1 ,25(OH)D3 are not responsible for the skeletal
resistance to PTH in dogs with chronic renal failure.
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